Urology
Volume 73, Issue 5, Supplement , Pages S36-S43 , May 2009

Overview of Pivotal Studies for Prostate Cancer Risk Reduction, Past and Present

  • Gerald L. Andriole

      Affiliations

    • Corresponding Author InformationReprint requests: Gerald Andriole, M.D., Division of Urology, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, Siteman Cancer Center, 4960 Children's Place, Campus Box 8242, St. Louis, MO 63110

Received 2 February 2009 ,Accepted 13 February 2009.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  2. Delongchamps NB, Singh A, Haas GP. The role of prevalence in the diagnosis of prostate cancer. Cancer Control. 2006;13:158–168
  3. Ries L, Melbert D, Drapcho M, et al. SEER cancer statistics review (based on November 2007 SEER data submission, posted to the SEER Web site, 2008). http://seer.cancer.gov/csr/1975_2005/Accessed May 30, 2008
  4. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–1261
  5. Marks LS. 5α-reductase: history and clinical importance. Rev Urol. 2004;6(suppl 9):S11–S21
  6. Wilbert DM, Griffin JE, Wilson JD. Characterization of the cytosol androgen receptor of the human prostate. J Clin Endocrinol Metab. 1983;56:113–120
  7. Ross RK, Bernstein L, Lobo RA, et al. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992;339:887–889
  8. Ntais C, Polycarpou A, Tsatsoulis A. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol. 2003;149:469–477
  9. Jin Y, Penning TM. Steroid 5α-reductases and 3α-hydroxysteroid dehydrogenases: key enzymes in androgen metabolism. Best Pract Res Clin Endocrinol Metab. 2001;15:79–94
  10. Thomas LN, Lazier CB, Gupta R, et al. Differential alterations in 5α-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate. 2005;63:231–239
  11. Bostwick DG. Prostatic intraepithelial neoplasia is a risk factor for cancer. Semin Urol Oncol. 1999;17:187–198
  12. Cote RJ, Skinner EC, Salem CE, et al. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. Br J Cancer. 1998;78:413–418
  13. Andriole GL, Humphrey P, Ray P, et al. Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol. 2004;172:915–919
  14. Uemura M, Tamura K, Chung S, et al. Novel 5 α-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci. 2008;99:81–86
  15. Avodart® (dutasteride) prescribing information. Research Triangle Park, NC: GlaxoSmithKline; 2008;
  16. Proscar® (finasteride) Prescribing Information. Whitehouse Station, NJ: Merck & Company; 2007;
  17. Bramson HN, Hermann D, Batchelor KW, et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997;282:1496–1502
  18. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, et al. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α-reductase inhibitors GI198745 and finasteride. Clin Pharmacol Ther. 1998;64:636–647
  19. Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab. 2004;89:2179–2184
  20. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224
  21. Feigl P, Blumenstein B, Thompson I, et al. Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials. 1995;16:150–163
  22. Higgins B, Thompson IM. The Prostate Cancer Prevention Trial: current status. J Urol. 2004;171(2 Pt. 2):S15–S17
  23. Guess HA, Heyse JF, Gormley GJ, et al. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia: results from the North American phase III clinical trial. Urol Clin North Am. 1993;20:627–636
  24. Andriole GL, Guess HA, Epstein JI, et al. Proscar Long-term Efficacy and Safety Study, PLESS Study Group Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. Urology. 1998;52:195–201
  25. Gormley GJ, Stoner E, Bruskewitz RC, et al. Finasteride Study Group The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 1992;327:1185–1191
  26. Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:1025–1035
  27. Mellon JK. The finasteride Prostate Cancer Prevention Trial (PCPT)—what have we learned?. Eur J Cancer. 2005;41:2016–2022
  28. Thompson IM, Tangen CM, Goodman PJ, et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol. 2007;177:1749–1752
  29. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98:1128–1133
  30. Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99:1375–1383
  31. Pinsky P, Parnes H, Ford L. Estimating rates of true high-grade disease in the Prostate Cancer Prevention Trial. Cancer Prev Res. 2008;1:182–186
  32. Redman MW, Tangen CM, Goodman PJ, et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res. 2008;1:174–181
  33. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529–534
  34. Pepe MS, Feng Z, Huang Y, et al. Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol. 2008;167:362–368
  35. Lazier CB, Thomas LN, Douglas RC, et al. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate. 2004;58:130–144
  36. Andriole GL, Roehrborn C, Schulman C, et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology. 2004;64:537–541
  37. Andriole GL, Kirby R. Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003;44:82–88
  38. Debruyne F, Barkin J, Van Erps P, et al. Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46:488–494
  39. Djavan B, Milani S, Fong YK. Dutasteride: a novel dual inhibitor of 5α-reductase for benign prostatic hyperplasia. Expert Opin Pharmacother. 2005;6:311–317
  40. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol. 2004;172(4 Pt. 1):1314–1317
  41. Gomella LG. Chemoprevention using dutasteride: the REDUCE trial. Curr Opin Urol. 2005;15:29–32
  42. Iczkowski KA, Qiu J, Qian J, et al. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology. 2005;65:76–82
  43. Fleshner N, Gomella LG, Cookson MS, et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials. 2007;28:763–769
  44. Furr BJ, Tucker H. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology. 1996;47(suppl):13–25
  45. GlaxoSmithKline. Data on file. Brentford, Middlesex, United Kingdom: GlaxoSmithKline; 2008;
  46. Clark LC, Combs GF, Turnbull BW, et al. Nutritional Prevention of Cancer Study Group Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. JAMA. 1996;276:1957–1963
  47. Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with α-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst. 1998;90:440–446
  48. Klein EA, Lippman SM, Thompson IM, et al. The Selenium and Vitamin E Cancer Prevention Trial. World J Urol. 2003;21:21–27
  49. National Cancer Institute. Review of prostate cancer prevention study shows no benefit for use of selenium and vitamin E supplements (Press release 2008). http://www.cancer.gov/newscenter/pressreleases/SELECTresults2008Accessed November 17, 2008

 G. L. Andriole serves as a consultant to Aeterna Zentaris, Nema Steba, Onconome, and GlaxoSmithKline and has received research funding from Envisioneering, Ferring Pharmaceuticals, GlaxoSmithKline, Veridex, Viking Medical, and Zeneca.

PII: S0090-4295(09)00238-6

doi: 10.1016/j.urology.2009.02.017

Urology
Volume 73, Issue 5, Supplement , Pages S36-S43 , May 2009

Article Tools

* Image Usage & Resolution